References
- Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117–28.
- http://www.ecancermedicalscience.com/cache/pdf/ECRM%20LR%20Survey.pdf.
- Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, et al. Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer 2011;47:1468–75.
- LoConte NK, Cleary JF, Bozeman J, Wilding G, Alberti D, Setala A, et al. Predictors of dose limiting toxicities in phase I clinical trials: the impact of age, comorbidity, and other clinical and non-clinical factors. J Clin Oncol 2008;15S:9525.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16.
- Schilsky L. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8:935–8.
- http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.